Singer Jesy Nelson recently shared an emotional update regarding the complications she is experiencing in her pregnancy with twin babies. Former Little Mix singer Jesy, who is having twins with partner Zion Foster, announced that she has been diagnosed with pre-twin-to-twin transfusion syndrome (pre-TTTS). The condition, which is present in pregnancies involving twins with a shared placenta, has serious risks involved and needs intense medical supervision. As Nelson embarks on this difficult journey, her story enlightens us about a rare but dangerous condition many expectant parents may not know much about.

Twin-to-twin transfusion syndrome is a rare but dangerous condition that arises in monochorionic twin pregnancies, in which identical twins share a single placenta. The placenta supplies the developing babies with oxygen, nutrients, and blood flow, but in TTTS, there is an imbalance of blood vessels that interconnect the twins, and thus the vital resources are not evenly distributed. One twin, or the donor twin, shares excess blood with the other, referred to as the recipient twin. This leads to one baby becoming malnourished and possibly anemic, and the other in danger of heart problems due to too much blood.

Nelson described her diagnosis in a heartfelt Instagram video, explaining that she is currently in the pre-stage of TTTS and undergoing frequent monitoring. "I am being scanned twice a week, and each time, things have gotten a little worse," she shared, expressing her fears and hopes for the health of her babies.

Potential Risks of TTTS

If left untreated, TTTS can have devastating consequences. Medical research indicates that:

• 90% of the cases of untreated TTTS lead to loss of one or both twins.
• Despite treatment, only a 70% survival rate for both twins is assured.
• Severe forms can result in preterm labor, cardiac failure in the recipient twin, and organ failure in the donor twin.
• Complications in long-term survivors include neurological damage and developmental delay in surviving infants.

TTTS usually advances in stages, beginning with minimal changes in fluid levels and worsening as one twin continues to get an unequal share of blood. In extreme cases, fetal laser surgery, referred to as the Solomon technique, can be employed to divide the blood vessels and balance the twins.

Why Identical Twin Pregnancies Are More Complicated

Identical twins may develop differently, and their own unique form of placental sharing can have a dramatic effect on pregnancy risk. Jesy Nelson's twins are considered monochorionic diamniotic (mono/di), which means they share a placenta but have two amniotic sacs. This is the type of pregnancy in about 70% of identical twin pregnancies and carries an increased risk of complications like TTTS, umbilical cord entanglement, and growth restriction.

Conversely, dichorionic diamniotic (di/di) twins both have a separate placenta and amniotic sac, which greatly diminishes the threat of TTTS. Twin pregnancy type is normally identified by early ultrasound, with physicians being able to track future complications from inception.

Other Twin Pregnancy Health Risks

Twin pregnancies, even without the presence of TTTS, entail a variety of health risks to the mother as well as infants:

1. Premature Birth

Over 60% of twin pregnancies end in premature delivery, with birth usually taking place before 37 weeks. Premature infants can have immature organs and need neonatal intensive care (NICU) assistance to assist with breathing, feeding, and infection fighting.

2. Gestational Hypertension and Preeclampsia

Pregnant women with multiples are at increased risk of having high blood pressure during pregnancy. This, if left untreated, can result in preeclampsia, a serious complication of pregnancy that can result in damage to organs, preterm labor, and in some cases, maternal or fetal death.

3. Anemia

Pregnant women carrying multiples are twice as likely to experience anemia, a condition where the body does not produce enough healthy red blood cells. This can lead to fatigue, dizziness, and complications during delivery.

4. Birth Defects

According to John Hopkins Medicine, multiple birth babies are twice as likely to have congenital abnormalities compared to single births. These can include heart defects, neural tube defects, and gastrointestinal issues.

5. Amniotic Fluid Imbalances

When twins have to share a placenta, they are more likely to have polyhydramnios (excess amniotic fluid) or oligohydramnios (not enough amniotic fluid). Both result in distress to the babies during fetal development and can result in premature labor.

6. Postpartum Hemorrhage

Twins are at increased risk of excessive postpartum hemorrhage because their uterus is larger and there are greater blood supply needs.

Jesy Nelson's openness about her challenging experience is raising awareness for TTTS, a condition that few individuals—let alone expectant mothers and fathers—might be aware of. Through her tearful video, Nelson stressed the significance of knowing about twin pregnancies aside from the thrill of having multiples. "We had no idea that this type of thing occurs when you're having twins. We just desperately want to make people aware of this because there are so many people who aren't aware."

Her case reminds us of the intricacies involved in twin pregnancy and the significance of early identification and medical management. For mothers carrying twins, frequent ultrasounds and vigilance can become a life-and-death issue for early detection and better outcomes of both babies.

Through constant medical attention and care, she and her partner Zion Foster remain positive and get ready for their babies to be born. In other parents whose situations are no different, the story of Nelson highlights awareness, medical progress, and emotional encouragement in handling complicated pregnancies.

The expecting parents of twin siblings are advised to discuss TTTS screening and possible interventions with their physicians to give their babies the best chance.

We may now have a clearer explanation behind ‘mommy brain’ or ‘momnesia’. Walking into a room and forgetting why you went there or losing track of a conversation is not simply a side effect of becoming a mother.

A new study has discerned a possible explanation for the phenomenon commonly known as “momnesia,” “pregnancy brain” or “mommy brain”. The findings were published in Science Bulletin.

According to the study, persistent high levels of estrogen during pregnancy may disrupt a particular brain circuit involved in memory.

Researchers found that high estrogen affected communication between the hypothalamus and hippocampus, two brain regions involved in regulating different aspects of brain function, including memory.

What Is “Momnesia”?

Pregnancy-related forgetfulness is generally considered to be temporary changes in memory and cognition during pregnancy.

Researchers say forgetfulness can become noticeable in late pregnancy stage and may continue well into the postpartum period before improving.

Women may have trouble recalling names or words, keeping track of events or completing everyday tasks.

According to the author of the study Dr Zheng Sun of Baylor College of Medicine, about 80% of pregnant women report these changes. The researchers say that this condition does not appear to be a decline in intelligence or cognitive ability.

According to Reuters, Dr Yanlin He, another study leader, said, “The important point is that pregnancy does not simply make someone ‘less intelligent.’ The effects appear to be more subtle and specific to certain cognitive tasks.”

Also read: Vitamin D & Pregnancy: Could Vitamin D Deficiency Increase Risk Of Premature Birth?

Link Between Pregnancy Hormones And Memory

During pregnancy, estrogen levels increase drastically and reach its peak during the third trimester.

The researchers focused on estrogen receptor alpha in neurons located in the lateral hypothalamus. In experiments based on mice who were exposed to high estrogen level conditions like in pregnancy, these neurons became more active.

Those neurons send signals to the hippocampus, a brain region crucial for memory formation. The researchers found that increased activity in this region suppressed hippocampal activity and impaired performance on memory tests.

When researchers switched off the hypothalamus-to-hippocampus pathway, the memory problems in the mice were prevented. Activating the pathway, meanwhile, impaired memory even without elevated estrogen.

Removing estrogen receptors from the hypothalamic neurons also reversed the estrogen-related memory problems in the mice.

Also read: Preeclampsia May End With Pregnancy. Your Heart Risk May Not

Does Pregnancy Actually Make You Forgetful?

The researchers also assessed memory in 70 women, including women at different stages of pregnancy and women who were not pregnant.

Memory problems surfaced during late pregnancy stages and were linked with higher circulating estrogen levels. The researchers reported changes across several memory-related tasks.

But it is important to note that the researchers did not directly measure or manipulate this specific brain circuit in pregnant women. That means the human findings support the mechanism observed in mice, but do not prove that exactly the same circuit causes memory changes during human pregnancy.

The study has cemented evidence that many pregnant women experience forgetfulness, but it does not mean pregnancy causes permanent memory loss. For most women, pregnancy-related forgetfulness generally improves after childbirth.

Novo Nordisk's next-generation obesity drug CagriSema has delivered greater weight loss than a lower dose of Eli Lilly's tirzepatide in a new late-stage trial. The trial has given giving the Danish drugmaker new evidence for its upcoming weight loss injectable as it competes in the rapidly expanding GLP-1 obesity drug market.

In the Phase 3 REIMAGINE 5 trial, adults with type 2 diabetes receiving CagriSema lost an estimated 12.4% of their body weight after 60 weeks, compared with 9.1% among those receiving 5 mg of tirzepatide, the active ingredient in Lilly's Mounjaro and Zepbound. CagriSema also resulted reduction in HbA1c, a measure of average blood sugar.

However, the trial compared 1 mg/1 mg CagriSema to 5 mg tirzepatide, rather than the highest doses used in obesity treatment. Earlier this year, a separate Phase 3 trial in people with obesity found that CagriSema did not meet its goal against high-dose 15 mg tirzepatide. At 84 weeks, CagriSema resulted in 23% weight loss compared to 25.5% with tirzepatide.

What Is CagriSema?

CagriSema is a once-weekly injection that combines two active ingredients: semaglutide and cagrilintide.

Semaglutide is the active ingredient in Novo's Wegovy and Ozempic. It belongs to the GLP-1 receptor agonist class and helps reduce appetite and food intake. Cagrilintide mimics amylin, a hormone involved in appetite regulation and feelings of fullness. By combining the two medicines, Novo is attempting to produce greater weight loss results.

Unlike Wegovy and Ozempic, however, CagriSema is still investigational. Novo submitted it to the US FDA for weight management in December 2025. The regulatory decision is expected in the fourth quarter of 2026.

Also read: Hundreds Of American GLP-1 Users Sue Novo Nordisk, Eli Lilly Over Vision Loss: What Is NAION?

What Did The New Trial Find?

REIMAGINE 5 is based on adults with type 2 diabetes whose blood sugar was not controlled properly with metformin, an SGLT2 inhibitor or both. After 60 weeks, CagriSema showed 12.4% average weight loss. Tirzepatide 5 mg resulted in 9.1% average weight loss.

CagriSema showed 1.71% HbA1c reduction while tirzepatide resulted in 1.67%.

Novo said the combination was generally well tolerated. Gastrointestinal side effects are among the common adverse effects that were seen with the treatment.

Novo's chief scientific officer Martin Holst Lange called the findings “very encouraging” and said they strengthen the company's confidence in CagriSema's potential.

Also read: Blood Test That Could Detect 50+ Cancers Closer To Approval As FDA Raises No Major Concerns About Its Accuracy

Is CagriSema Better Than Mounjaro Or Zepbound?

The new study establishes that CagriSema outperformed 5 mg tirzepatide for weight loss in this particular population sample with type 2 diabetes.

But tirzepatide is available at substantially higher doses, and the earlier obesity head-to-head trial compared CagriSema with 15 mg tirzepatide, where tirzepatide produced better weight loss results.

Therefore, the company has not declared that CagriSema consistently produces more weight loss than tirzepatide across all trials.

CagriSema is Novo's attempt to move beyond single-pathway GLP-1 treatment by combining GLP-1 and amylin biology. In another new Phase 3 trial, REDEFINE 9, CagriSema produced 21% weight loss after 68 weeks, compared with 2% with placebo, in adults with overweight or obesity.

Hundreds of GLP-1 users in the US are suing drugmakers Novo Nordisk and Eli Lilly, alleging they developed a rare form of sudden vision loss called nonarteritic anterior ischemic optic neuropathy (NAION) after taking drugs such as Ozempic, Wegovy and Mounjaro.

The lawsuits allege the companies failed to adequately warn patients about the potential risk, that is often irreversible.

What Is The Controversy?

US law firm Weitz & Luxenberg has filed more than 90 lawsuits in New Jersey state court since 2025 on behalf of people who say they developed NAION while taking Ozempic or Wegovy, according to The Wall Street Journal.

Separate federal lawsuits in Philadelphia accuse Novo Nordisk and Eli Lilly of failing to provide adequate warnings about the potential eye-related risk. The cases are pending.

Regulators in Europe and Australia have required warnings about a possible increased risk of NAION with some GLP-1 medicines after reviewing available evidence.

In the US, vision problems are listed as possible side effects, but the FDA does not currently require NAION to be listed as a specific risk. The FDA's Sentinel Initiative is reviewing the possible safety signal linking GLP-1 drugs to NAION.

"The FDA routinely monitors the safety of drug products post-marketing. The FDA identifies safety signals from a variety of sources, evaluates the available data and takes regulatory actions when appropriate,” an FDA spokesperson said, according to ABC News.

Also read: Ozempic, Wegovy, Mounjaro and Zepbound May Fuel Rare Brain Disorder, Study Finds

What Do The Drugmakers Say?

Novo Nordisk, which makes Ozempic and Wegovy, said it takes “all reports of adverse events very seriously” but called the personal injury lawsuits "without merit."

The company said it is "committed to patient safety and continuously monitors the safety profile of our GLP-1 RA products." It added that if "emerging safety data warrant further action, appropriate measures will be implemented".

Lilly, which makes Zepbound and Mounjaro, said patient safety is its "top priority."

"We actively monitor, evaluate, and report safety information for all our medicines to the FDA," the company said, adding that it continues to review data on potential ophthalmic issues.

What Does The Science Say?

The evidence linking GLP-1 drugs to NAION remains mixed. Some observational studies have found an association, while others have not. Researchers have not established that GLP-1 drugs cause NAION.

What Studies Have Found

• 2025 JAMA study: Among more than 159,000 people with type 2 diabetes, 35 GLP-1 users developed NAION versus 19 in the comparison group. Researchers also found an increased risk of other optic nerve disorders in 93 patients.
• Another 2025 JAMA study: Found no statistically significant association between GLP-1 use and NAION, although it reported a slight increase in diabetic retinopathy.
• 2026 safety analysis: A British Journal of Ophthalmology analysis of more than 30 million FDA adverse-event reports from 2017 to 2024 identified a safety signal linking semaglutide medicines to NAION.
• Wegovy vs Ozempic: The signal was nearly five times stronger for Wegovy than Ozempic, although both contain semaglutide.

The North American Neuro-Ophthalmology Society and American Academy of Ophthalmology said studies have produced mixed results.

"While many report a small possible increased risk of NAION in patients taking GLP-1 RAs such as semaglutide, some studies report no correlation, and the overall magnitude of the risk of NAION remains low,” the groups said.

Read More: Exclusive: GLP-1 Drugs Are The ‘New Statins’, Says University Hospital Birmingham Professor

What Is NAION?

NAION is the most common acute optic neuropathy in people over 50, according to Mayo Clinic. It occurs when blood flow to the optic nerve is suddenly reduced, damaging the nerve that carries visual information from the eye to the brain.

It typically causes painless vision loss in one eye.

Some patients experience partial improvement, but vision loss is often permanent. There is currently no proven treatment to reverse the damage.

Diabetes itself can increase the risk of NAION, regardless of GLP-1 use. Other risk factors include overnight low blood pressure and having a very small optic nerve cup.